Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Research & Development (2013 - 2026)

Scynexis' (SCYX) quarterly Research & Development came in at $3.9 million in Q2 2026, down 45.51% on a YoY basis from $7.1 million in Q2 2025, and down 68.5% quarter-over-quarter from $12.4 million in Q1 2026.

Analysis

Scynexis (SCYX) Research & Development (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Research & Development for 14 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Research & Development fell 45.51% year-over-year to $3.9 million; the trailing twelve-month figure through Jun 2026 stood at $26.2 million (up 6.36% YoY), and the FY2025 full-year result was $22.3 million, down 15.62% from the prior year.
  • Research & Development retreated to $3.9 million in Q2 2026 per SCYX's latest filing, from $12.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $12.4 million in Q1 2026 and bottomed at $3.9 million in Q2 2026.
  • Historically, Research & Development has averaged $6.8 million across 5 years, with a median of $6.8 million in 2023.
  • The sharpest annual moves came in 2024 and 2026: Research & Development tumbled 59.25% in 2024, then soared 140.25% in 2026.
  • Over 5 years, Research & Development stood at $7.8 million in 2022, then jumped by 34.87% to $10.6 million in 2023, then sank by 59.25% to $4.3 million in 2024, then increased by 5.35% to $4.5 million in 2025, then slipped by 14.39% to $3.9 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods registered $3.9 million, $12.4 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -486.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 202.02 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 3.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.89 Mn
Mar 31, 2026 12.35 Mn
Dec 31, 2025 4.55 Mn
Sep 30, 2025 5.45 Mn
Jun 30, 2025 7.14 Mn
Mar 31, 2025 5.14 Mn
Dec 31, 2024 4.31 Mn
Sep 30, 2024 8.07 Mn
Jun 30, 2024 6.81 Mn
Mar 31, 2024 7.21 Mn
Dec 31, 2023 10.59 Mn
Sep 30, 2023 6.47 Mn
Jun 30, 2023 7.04 Mn
Mar 31, 2023 6.84 Mn
Dec 31, 2022 7.85 Mn
Sep 30, 2022 6.43 Mn
Jun 30, 2022 7.13 Mn
Mar 31, 2022 5.74 Mn
Dec 31, 2021 7.69 Mn
Sep 30, 2021 4.40 Mn